Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats

References

• Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci. 2010;11(12):823–836.
   PubMed Web of Science ®Google Scholar
• Sherrington CS. Qualitative difference of spinal reflex corresponding with qualitative difference of cutaneous stimulus. J Physiol. 1903;30:39–46.
   PubMedGoogle Scholar
• Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell. 2009;139:267–284.
   PubMed Web of Science ®Google Scholar
• Willis WD. Sensory mechanisms of the spinal cord volume 1 primary afferent neurons and the spinal dorsal horn. Boston (MA): Boston (MA): Springer US: Imprint: Springer; 2004.
   Google Scholar
• Black JA, Frezel N, Dib-Hajj SD, et al. Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn. Mol Pain. 2012;8:82.
   PubMed Web of Science ®Google Scholar
• Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci. 1998;18:9607–9619.
   PubMed Web of Science ®Google Scholar
• Herzog RI, Cummins TR, Ghassemi F, et al. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol. 2003;551:741–750.
   PubMed Web of Science ®Google Scholar
• Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007;117:3603–3609.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41:171–174.
   PubMed Web of Science ®Google Scholar
• Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52(5):767–774.
   PubMed Web of Science ®Google Scholar
• Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894–898.
   PubMed Web of Science ®Google Scholar
• Alexandrou AJ, Brown AR, Chapman ML, et al. SubtypeSelective small molecule inhibitors reveal a fundamental role for Nav1.7 in nociceptor electrogenesis, axonal conduction and presynaptic release. PLoS One. 2016;11:e0152405.
   PubMed Web of Science ®Google Scholar
• McCormack K, Santos S, Chapman ML, et al. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. Proc Natl Acad Sci U S A. 2013;110:E2724–32.
   PubMed Web of Science ®Google Scholar
• Siebenga P, van Amerongen G, Hay JL, et al. Lack of detection of the analgesic properties of PF-05089771, a selective Na(v) 1.7 inhibitor, using a battery of pain models in healthy subjects. Clin Transl Sci. 2020;13:318–324.
   PubMed Web of Science ®Google Scholar
• Eagles DA, Chow CY, King GF. Fifteen years of NaV1.7 channels as an analgesic target: why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy?. Br J Pharmacol. 2020 Nov 18. doi:10.1111/bph.15327.
   PubMed Web of Science ®Google Scholar
• Goodwin G, McMahon SB. The physiological function of different voltage-gated sodium channels in pain. Nat Rev Neurosci. 2021;22:263–274.
   PubMed Web of Science ®Google Scholar
• Dustrude ET, Wilson SM, Ju W, et al. CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking. J Biol Chem. 2013;288:24316–24331.
   PubMed Web of Science ®Google Scholar
• Dustrude ET, Moutal A, Yang X, et al. Hierarchical CRMP2 posttranslational modifications control NaV1.7 function. Proc Natl Acad Sci U S A. 2016;113:E8443–E52.
   PubMed Web of Science ®Google Scholar
• Dustrude ET, Perez-Miller S, Francois-Moutal L, et al. A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. Channels (Austin). 2017;11:316–328.
   PubMed Web of Science ®Google Scholar
• Francois-Moutal L, Dustrude ET, Wang Y, et al. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. Pain. 2018;159:2115–2127.
   PubMed Web of Science ®Google Scholar
• Chew LA, Khanna R. CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain. Neuronal Signaling. 2018;2:NS20170220.
   PubMedGoogle Scholar
• Chew LA, Bellampalli SS, Dustrude ET, et al. Mining the Nav1.7 interactome: opportunities for chronic pain therapeutics. Biochem Pharmacol. 2019;163:9–20.
   PubMed Web of Science ®Google Scholar
• Stratton H, Boinon L, Moutal A, et al. Coordinating synaptic signaling with CRMP2. Int J Biochem Cell Biol. 2020;124:105759.
   PubMed Web of Science ®Google Scholar
• Moutal A, Ji Y, Bellampalli SS, et al. Differential expression of Cdk5 phosphorylated CRMP2 following a spared nerve injury. Mol Brain. 2020;13:97.
   PubMed Web of Science ®Google Scholar
• Moutal A, Cai S, Yu J, et al. Studies on CRMP2 SUMOylation-deficient transgenic mice identify sex-specific Nav1.7 regulation in the pathogenesis of chronic neuropathic pain. Pain. 2020;161:2629–2651.
   PubMed Web of Science ®Google Scholar
• Gomez K, Ran D, Madura CL, et al. Non-SUMOylated CRMP2 decreases Na(V)1.7 currents via the endocytic proteins Numb, Nedd4-2 and Eps15. Mol Brain. 2021;14:20.
   PubMed Web of Science ®Google Scholar
• Cai S, Moutal A, Yu J, et al. Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Sci Transl Med. 2021;13:eabh1314.
   PubMed Web of Science ®Google Scholar
• Brittain JM, Chen L, Wilson SM, et al. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J Biol Chem. 2011;286:37778–37792.
   PubMed Web of Science ®Google Scholar
• Brittain JM, Pan R, You H, et al. Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Channels (Austin). 2012;6:52–59.
   PubMed Web of Science ®Google Scholar
• Brittain MK, Brustovetsky T, Sheets PL, et al. Delayed calcium dysregulation in neurons requires both the NMDA receptor and the reverse Na+/Ca2+ exchanger. Neurobiol Dis. 2012;46:109–117.
   PubMed Web of Science ®Google Scholar
• Brustovetsky T, Pellman JJ, Yang XF, et al. Collapsin response mediator protein 2 (CRMP2) interacts with N-methyl-D-aspartate (NMDA) receptor and Na+/Ca2+ exchanger and regulates their functional activity. J Biol Chem. 2014;289:7470–7482.
   PubMed Web of Science ®Google Scholar
• Ji Y, Hu Y, Ren J, et al. CRMP2-derived peptide ST2-104 (R9-CBD3) protects SH-SY5Y neuroblastoma cells against Abeta 25-35-induced neurotoxicity by inhibiting the pCRMP2/NMDAR2B signaling pathway. Chem Biol Interact. 2019;305:28–39.
   PubMed Web of Science ®Google Scholar
• Yu H, Shin SM, Xiang H, et al. AAV-encoded CaV2.2 peptide aptamer CBD3A6K for primary sensory neuron-targeted treatment of established neuropathic pain. Gene Ther. 2019;26:308–323.
   PubMed Web of Science ®Google Scholar
• Buchta WC, Moutal A, Hines B, et al. Dynamic CRMP2 regulation of CaV2.2 in the prefrontal cortex contributes to the reinstatement of cocaine seeking. Mol Neurobiol. 2019;57:346–357.
   PubMed Web of Science ®Google Scholar
• Yu J, Moutal A, Dorame A, et al. Phosphorylated CRMP2 regulates spinal nociceptive neurotransmission. Mol Neurobiol. 2019;56:5241–5255.
   PubMed Web of Science ®Google Scholar
• Moutal A, Sun L, Yang X, et al. CRMP2-neurofibromin interface drives NF1-related pain. Neuroscience. 2018;381:79–90.
   PubMed Web of Science ®Google Scholar
• Moutal A, Wang Y, Yang X, et al. Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors. Pain. 2017;158:2203–2221.
   PubMed Web of Science ®Google Scholar
• Moutal A, Yang X, Li W, et al. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain. 2017;158:2301–2319.
   PubMed Web of Science ®Google Scholar
• Moutal A, Francois-Moutal L, Perez-Miller S, et al. (S)Lacosamide binding to collapsin response mediator protein 2 (CRMP2) regulates CaV2.2 activity by subverting its phosphorylation by Cdk5. Mol Neurobiol. 2016;53:1959–1976.
   PubMed Web of Science ®Google Scholar
• Moutal A, Chew LA, Yang X, et al. (S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. Pain. 2016;157:1448–1463.
   PubMed Web of Science ®Google Scholar
• Francois-Moutal L, Wang Y, Moutal A, et al. A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain. 2015;156:1247–1264.
   PubMed Web of Science ®Google Scholar
• Ju W, Li Q, Wilson SM, et al. SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons. Channels (Austin). 2013;7:153–159.
   PubMed Web of Science ®Google Scholar
• Piekarz AD, Due MR, Khanna M, et al. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol Pain. 2012;8:54.
   PubMed Web of Science ®Google Scholar
• Wilson SM, Schmutzler BS, Brittain JM, et al. Inhibition of transmitter release and attenuation of AIDS therapy-induced and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides. J Biol Chem. 2012;287:35065–35077.
   PubMed Web of Science ®Google Scholar
• Ripsch MS, Ballard CJ, Khanna M, et al. A peptide uncoupling CRMP-2 from the presynaptic Ca2+ channel complex demonstrate efficacy in animal models of migraine and AIDS therapy-induced neuropathy. Transl Neurosci. 2012;3:1–8.
   PubMed Web of Science ®Google Scholar
• Brittain JM, Wang Y, Eruvwetere O, et al. Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2. FEBS Lett. 2012;586:3813–3818.
   PubMed Web of Science ®Google Scholar
• Ju W, Li Q, Allette YM, et al. Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginineconjugated CRMP2 peptide. J Neurochem. 2012;124:869–879.
   Web of Science ®Google Scholar
• Brittain JM, Duarte DB, Wilson SM, et al. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel complex. Nat Med. 2011;17:822–829.
   PubMed Web of Science ®Google Scholar
• Moutal A, Dustrude ET, Largent-Milnes TM, et al. Blocking CRMP2 SUMOylation reverses neuropathic pain. Mol Psychiatry. 2018;23:211921.
   Web of Science ®Google Scholar
• de Macedo FHP, Aires RD, Fonseca EG, et al. TNF-α mediated upregulation of Na(V)1.7 currents in rat dorsal root ganglion neurons is independent of CRMP2 SUMOylation. Mol Brain. 2019;12:117.
   PubMed Web of Science ®Google Scholar
• Francois-Moutal L, Scott DD, Perez-Miller S, et al. Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels. Channels (Austin). 2018;12:219–227.
   PubMed Web of Science ®Google Scholar
• Uchida Y, Ohshima T, Yamashita N, et al. Semaphorin3A signaling mediated by Fyn-dependent tyrosine phosphorylation of collapsin response mediator protein 2 at tyrosine 32. J Biol Chem. 2009;284:27393–27401.
   PubMed Web of Science ®Google Scholar
• Varrin-Doyer M, Vincent P, Cavagna S, et al. Phosphorylation of collapsin response mediator protein 2 on Tyr-479 regulates CXCL12induced T lymphocyte migration. J Biol Chem. 2009;284:13265–13276.
   PubMed Web of Science ®Google Scholar
• Morinaka A, Yamada M, Itofusa R, et al. Thioredoxin mediates oxidation-dependent phosphorylation of CRMP2 and growth cone collapse. Sci Signal. 2011;4:ra26.
   PubMed Web of Science ®Google Scholar
• Khanna R, Wilson SM, Brittain JM, et al. Opening Pandora’s jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. Future Neurol. 2012;7:749–771.
   PubMedGoogle Scholar
• Sadler KE, Mogil JS, Stucky CL. Innovations and advances in modelling and measuring pain in animals. Nat Rev Neurosci. 2021. DOI:10.1038/s41583-021-00536-7
   PubMed Web of Science ®Google Scholar
• Berge O-G. Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol. 2011;164:1195–1206.
   PubMed Web of Science ®Google Scholar
• Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87–107.
   PubMed Web of Science ®Google Scholar
• Odem MA, Lacagnina MJ, Katzen SL, et al. Sham surgeries for central and peripheral neural injuries persistently enhance pain-avoidance behavior as revealed by an operant conflict test. Pain. 2019;160:2440–2455.
   PubMed Web of Science ®Google Scholar
• Kingwell K. Navigating a new path to Nav1.7 for pain. Nat Rev Drug Discov. 2021. DOI:10.1038/d41573-021-00197-2
   Web of Science ®Google Scholar
• Grace PM, Strand KA, Galer EL, et al. Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc Natl Acad Sci U S A. 2016;113:E3441–50.
   PubMed Web of Science ®Google Scholar
• Grace PM, Wang X, Strand KA, et al. DREADDed microglia in pain: implications for spinal inflammatory signaling in male rats. Exp Neurol. 2018;304:125–131.
   PubMed Web of Science ®Google Scholar
• Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative assessment of tactile allodynia in the rat paw. JNeurosciMethods. 1994;53:55–63.
   Web of Science ®Google Scholar
• Treutwein B, Strasburger H. Fitting the psychometric function. Percept Psychophys. 1999;61:87–106.
   PubMed Web of Science ®Google Scholar
• Harvey LO Jr. Efficient estimation of sensory thresholds with ML-PEST. Spat Vis. 1997;11:121–128.
   PubMedGoogle Scholar
• Li J, Ma J, Lacagnina MJ, et al. Oral dimethyl fumarate reduces peripheral neuropathic pain in rodents via NFE2L2 antioxidant signaling. Anesthesiology. 2020;132:343–356.
   PubMed Web of Science ®Google Scholar